Peptide CDMO supply-side differentiation: scale, cost, and technology breadth determine the winners
AI summary card
Peptide CDMO supply-side differentiation: scale, cost, and technology breadth determine the winners
Bernstein believes GLP-1 demand is channeling peptide CDMO industry growth toward a few platforms with large-scale capacity, low-cost structures, and complex conjugation technologies, with WuXi AppTec and Asymchem in more advantageous positions.
- The peptide CDMO industry remains highly fragmented, but growth is increasingly led by a few scaled platforms; the combined revenue of the four largest peptide CDMOs increased from approximately $1 Bn in 2021 to approximately $3 Bn in 2025.
- WuXi AppTec's TIDES revenue increased from approximately $120 Mn in 2021 to $1.7 Bn in 2025, while its market share rose from 11% to 54%; estimated 2025 peptide output was approximately 58 metric tons.
- Profitability differs significantly: WuXi AppTec achieved approximately a 47% gross margin and 37% EBIT margin in 2025, substantially above Bachem's approximately 22% EBIT margin, while PolyPeptide and EuroAPI were near breakeven.
- Technological differentiation lies not only in capacity, but also in peptide-oligonucleotide and radionuclide conjugation capabilities, green processes, waste management, and delivery speed from IND to NDA.
- The capacity of leading Chinese companies remains primarily concentrated in China. Although they have speed and cost advantages, they also face supply-chain concentration and geopolitical risks.
Report interpretation
Overview
This report is the first installment in Bernstein's peptide CDMO research series and focuses on the supply-side landscape. It divides global peptide CDMOs into three categories: large diversified CRDMOs, specialized peptide CDMOs, and long-tail regional suppliers. It notes that the rapid expansion of demand for GLP-1 and other metabolic peptides is changing the rules of competition: the industry is no longer determined solely by traditional specialized manufacturing experience, with capital investment, capacity ramp-up, metric-ton output, cost structure, and complex technology combinations becoming the core differentiators.
Core views
The core view is that although the peptide CDMO industry is fragmented, incremental growth is increasingly concentrating on scaled platforms. WuXi AppTec has established a significant supply-side advantage through early and aggressive capacity investment, high TIDES revenue growth, approximately 58 metric tons of output, and leading margins. Although Asymchem's 2025 revenue base was smaller, its growth is accelerating and new capacity is ramping up, giving it potential to gain market share in the future. By contrast, Western specialized peptide CDMOs such as Bachem and PolyPeptide retain advantages in technology and regulatory track records, but their growth and capital returns are weaker during the cycle of large-scale GLP-1 commercialization demand.
Analysis framework
The report adopts a supply-side industry comparison framework, benchmarking major global peptide CDMOs across market-share evolution, revenue growth, capacity and metric-ton output, commercial batch scale, regional capacity footprint, gross margin and EBIT margin, CapEx, ROIC, technology combinations, green processes, and development and delivery speed.
Methodology notes
Classifies participants into large diversified CRDMOs, specialized peptide CDMOs, and long-tail regional suppliers.
This framework explains why, following the expansion of GLP-1 demand, large CRDMOs with capital and integrated platform capabilities have begun to grow faster than traditional specialized peptide companies.
Uses metric tons of peptide output to assess manufacturing scale.
The report believes that kL reactor-volume disclosures are limited and are affected by peptide-chain length, loading quantity, yield, and batch configuration; metric-ton output better reflects actual commercial supply capacity.
Compares gross margin, EBIT margin, CapEx-to-sales, and ROIC.
This approach assesses whether companies can rapidly fill newly added capacity and convert large-scale investment into higher capital returns.
Compares capabilities in cyclic peptides, stapled peptides, peptide-small molecule, peptide-lipid, peptide-oligonucleotide, and radionuclide conjugates.
As multi-target and cross-modality drug development expands, conjugation technologies, green processes, and development speed are becoming important competitive barriers in addition to capacity.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- WuXi AppTecCore beneficiary and supply-side scale leader
- Strengths
- Rapid TIDES revenue growth, approximately 58 metric tons of peptide output in 2025, 47% gross margin, 37% EBIT margin, high ROIC, and a broad conjugation technology portfolio.
- Weaknesses
- Peptide capacity is currently concentrated mainly in China, while its global capacity footprint remains limited.
- Comparison
- Compared with Bachem, PolyPeptide, and EuroAPI, WuXi AppTec stands out in revenue growth, metric-ton output, capital returns, and margins.
- Risks
- Deterioration in service quality, rising attrition of integrated projects, loss of global-ex-China share due to geopolitical tensions, and higher-than-expected failure rates for new therapies.
- AsymchemPotential share gainer
- Strengths
- Peptide business grew 124% in 2025; disclosed 45kL of reactor capacity and plans to expand to 69kL, with a technology portfolio covering more complex peptide conjugates.
- Weaknesses
- Revenue base remains small, and capacity ramp-up and customer onboarding still require validation.
- Comparison
- Smaller than WuXi AppTec but growing faster; compared with traditional Western specialized manufacturers, it has the speed and expansion advantages of a Chinese CRDMO.
- Risks
- Insufficient utilization of new capacity, weaker-than-expected acquisition of large commercial orders, geopolitical risks, and customer requirements for supply-chain diversification.
- BachemRepresentative Western specialized peptide CDMO
- Strengths
- Long-standing specialized manufacturing experience, regulatory track record, manufacturing networks in Europe and North America, and strong green-process and waste-management capabilities.
- Weaknesses
- More moderate growth, higher CapEx-to-sales, and pressured ROIC during the expansion cycle.
- Comparison
- Strong in technology and regulatory experience, but its revenue growth and capital efficiency during the large-scale GLP-1 capacity cycle are weaker than WuXi AppTec's.
- Risks
- Slow filling of newly added capacity, higher cost structure, and dilution of market share by scaled CRDMOs.
- PolyPeptideRepresentative Western specialized peptide CDMO
- Strengths
- Focus on peptides and related modalities, with specialized manufacturing experience and an established customer base.
- Weaknesses
- Near breakeven in 2025, with growth weaker than that of Chinese CRDMOs.
- Comparison
- Like Bachem, it has specialization advantages, but trails WuXi AppTec in scale, margins, and growth.
- Risks
- Insufficient returns on capital expenditures, cost pressures, and concentration of large-scale GLP-1 orders on larger platforms.
- WuXi BiologicsOne of the covered stocks, rated Market-Perform
- Strengths
- The report discloses its target price and rating and uses DCF, P/E, and EV/EBITDA in its valuation methodology.
- Weaknesses
- The focus of this report is the peptide CDMO supply side, and WuXi Biologics is not a primary subject of the peptide supply-side analysis.
- Comparison
- Unlike the Outperform ratings for WuXi AppTec and Asymchem, WuXi Biologics is rated Market-Perform.
- Risks
- Weaker-than-expected performance in biologics and ADC businesses and weaker-than-expected acquisition of large commercial orders.
Key data
- Revenue of the four largest peptide CDMOsApproximately $1 Bn to $3 BnThe report states that combined revenue of leading peptide CDMOs expanded significantly from 2021 to 2025.
- WuXi AppTec TIDES revenueApproximately $120 Mn to $1.7 BnGrew at more than 70% CAGR from 2021 to 2025, with market share rising from 11% to 54%.
- Asymchem peptide revenue growth124% growth in 2025Revenue was approximately $152 Mn, but the business entered a rapid-growth phase.
- WuXi AppTec estimated peptide outputApproximately 58 metric tons in 2025The report considers it to be in a distinctly leading tier among major peptide CDMOs.
- Disclosed reactor capacityApproximately 100kL for WuXi AppTec and 45kL for Asymchem2025 disclosed figures; planned expansion to 130kL and 69kL, respectively, in 2026.
- WuXi AppTec profitabilityApproximately 47% gross margin and 37% EBIT margin2025 levels, which the report describes as significantly ahead of peers.
- Bachem EBIT marginApproximately 22%Leading among Western peptide players, but below WuXi AppTec.
- WuXi AppTec ROICApproximately 38% in 2025Driven by rapid utilization of newly built capacity and productivity improvements.
- Frequency of chemical synthesis use31 out of 38The report states that chemical synthesis routes were far more common than recombinant routes among recently approved peptide drugs.
Impact & implications
The investment implication is that competitive advantages in peptide CDMOs are shifting from standalone manufacturing experience toward integrated capabilities in scaled supply, cost efficiency, capital deployment, and complex technology platforms. If demand for GLP-1 and other metabolic peptides continues to grow, WuXi AppTec and Asymchem may continue to benefit from large-scale capacity and faster delivery capabilities. However, customer concerns about geographic supply-chain concentration and geopolitical risks may limit Chinese suppliers' share expansion in the global-ex-China market.
Risks
- Capacity of leading Chinese peptide CDMOs remains concentrated mainly in China, which may heighten customer concerns about supply-chain concentration and geopolitical risks.
- If demand for GLP-1 or other metabolic peptides falls short of expectations, utilization and ROIC for newly added capacity may come under pressure.
- Deteriorating service quality or rising attrition of integrated projects would weaken the advantages of CRDMO platforms.
- Higher-than-expected failure rates for new therapeutic modalities such as peptides, ADCs, or BsAbs could affect related CDMO demand.
- If Western specialized peptide companies improve capacity utilization or win large commercial orders, the current trend of Chinese CRDMOs gaining share could moderate.
What to watch
- Sustainability of commercial orders for GLP-1 and other metabolic peptides.
- WuXi AppTec TIDES revenue, capacity utilization, ROIC, and progress on Singapore capacity construction.
- Ramp-up of Asymchem's new peptide capacity, customer onboarding, and acquisition of commercial orders.
- Capacity-utilization and margin recovery at Western specialized manufacturers such as Bachem, PolyPeptide, and CordenPharma.
- Growth of complex conjugate pipelines, including peptide-oligonucleotide and radionuclide conjugates.
- Changes in customer attitudes toward concentration in Chinese supply chains and global-ex-China procurement strategies.